178452
载脂蛋白A-I，来源于人血浆，高密度脂蛋白
Native apolipoprotein A-I from human plasma. Functions as a cofactor for lecithin-cholesterol acyltransferase. A component of high density lipoprotein.
别名:
Apo A-I
产品名称
载脂蛋白A-I，来源于人血浆，高密度脂蛋白, Native apolipoprotein A-I from human plasma. Functions as a cofactor for lecithin-cholesterol acyltransferase. A component of high density lipoprotein.
assay
≥95% (SDS-PAGE)
form
liquid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
avoid repeated freeze/thaw cycles
shipped in
wet ice
storage temp.
−20°C
Quality Level
Disclaimer
仅供研究使用在法国，在用于科研目的时（包括进口和出口活动（《公共健康法》第L 1211-1条，第2节））该产品为管制品。购买者（即最终用户）需要获得《公共健康法》法第L 1211-1条规定的法国研究部的进口授权。订购本产品即表明您确认已经获得合适的进口授权。
毒性：标准处理（A）
General description
作为卵磷脂胆固醇酰基转移酶（LCAT）的辅助因子起作用。
来自人血浆的天然载脂蛋白A-I。作为卵磷脂胆固醇酰基转移酶（LCAT）的辅助因子起作用。它在HDL代谢中起重要作用。
Other Notes
Bergot, C., et al. 2001.Eur. J. Biochem.268, 3523.
Pászty, C., et al. 1994.J. Clin. Invest.94, 899.
Breslow, J.L.1993.Proc.Natl.Acad.Sci. USA90, 8314.
Schultz, J.R., et al. 1992.J. Biol. Chem.267, 21630.
Walsh, A., et al. 1989.J. Biol. Chem.264, 6488.
Brewer, H.B.1986.Methods Enzymol.128, 223.
Pászty, C., et al. 1994.J. Clin. Invest.94, 899.
Breslow, J.L.1993.Proc.Natl.Acad.Sci. USA90, 8314.
Schultz, J.R., et al. 1992.J. Biol. Chem.267, 21630.
Walsh, A., et al. 1989.J. Biol. Chem.264, 6488.
Brewer, H.B.1986.Methods Enzymol.128, 223.
Packaging
请参考特定浓度批号的标签。
Physical form
在10 mM NH₄HCO₃（pH 7.4）中。
Preparation Note
初次融化后，等分并冷冻（-20°C）。在浓度≥1 mg/ml下储存。
由经认证测试对HBsAg以及HIV和HCV抗体阴性的血浆制制备而成。
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
高风险级别生物产品-Merck
此项目有
Mengxi Wang et al.
Oxidative medicine and cellular longevity, 2022, 2226168-2226168 (2022-12-16)
At present, due to the limitations of drug therapy targets for atherosclerosis, some patients fail to achieve satisfactory efficacy. Cholesterol efflux dysfunction and endothelial cell inflammation are considered to be important factors in the development of atherosclerosis. Peroxisome proliferator-activated receptor
Remco Franssen et al.
Cholesterol, 2012, 610741-610741 (2012-05-23)
HDL provides atheroprotection by facilitating cholesterol efflex from lipid-laden macrophages in the vessel wall. In vitro studies have suggested impaired efflux capacity of HDL following inflammatory changes. We assessed the impact of acute severe sepsis and mild chronic inflammatory disease
Sanne J C M Frambach et al.
Life sciences, 300, 120571-120571 (2022-04-27)
Mitochondrial complex I (CI), the first multiprotein enzyme complex of the oxidative phosphorylation system, plays a crucial role in cellular energy production. CI deficiency is associated with a variety of clinical phenotypes, including Leigh syndrome. At the cellular level, an
Sylwia Wasiak et al.
Data in brief, 8, 1280-1288 (2016-08-30)
Apabetalone (RVX-208) inhibits the interaction between epigenetic regulators known as bromodomain and extraterminal (BET) proteins and acetyl-lysine marks on histone tails. Data presented here supports the manuscript published in Atherosclerosis "RVX-208, a BET-inhibitor for Treating Atherosclerotic Cardiovascular Disease, Raises ApoA-I/HDL
Jean-Baptiste Nyandwi et al.
International journal of molecular sciences, 22(16) (2021-08-28)
Lipid dysregulation in diabetes mellitus escalates endothelial dysfunction, the initial event in the development and progression of diabetic atherosclerosis. In addition, lipid-laden macrophage accumulation in the arterial wall plays a significant role in the pathology of diabetes-associated atherosclerosis. Therefore, inhibition
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持